{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T03:57:14Z","timestamp":1767585434049,"version":"3.48.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiographically occult peritoneal carcinomatosis (PC) is a major concern in gastric cancer; hence staging laparoscopy (SL) is recommended prior to initiating treatment, particularly neoadjuvant systemic therapy (NST). However, compliance may vary and could result in understaging. We sought to evaluate the utilization of SL in patients with gastric cancer referred to academic institutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This is a multi-institution retrospective study of patients with a diagnosis of gastric\/gastroesophageal junction (GEJ) Siewert 3 adenocarcinoma who received treatment between 2010 and 2022. Demographics, tumor characteristics, treatment, and recurrence data were collected. Descriptive statistics and multivariate analysis were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 280 patients with gastric\/GEJ cancer were identified, of which 75 (26.8%) had clinical stage IV disease and were excluded. Of the remaining 205 patients, 74 (36.1%) underwent upfront surgery and 131 (63.1%) underwent NST. Only 39 (29.8%) patients in the NST group underwent SL, of whom 15(38.4%) were found to have peritoneal metastases; 12 (80%) had gross PC and 3 (20%) had positive cytology. Among patients who underwent surgical resection after NST (\n                      <jats:italic>n<\/jats:italic>\n                      = 77), 26 (33.7%) experienced disease recurrence with a median time to recurrence of 11.6 months. The peritoneum (\n                      <jats:italic>n<\/jats:italic>\n                      = 10\/26, 38.5%) was the most common site of recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compliance with SL prior to NST is poor (29.8%), and in the group that underwent SL, 38% of patients were upstaged due to presence of peritoneal metastases. These findings are significant, as the management and prognosis of peritoneal metastases are drastically different. Various factors could lead to poor compliance with SL, hence better compliance and alternate approaches to reliably detect PC are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18547-4","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:59:40Z","timestamp":1760723980000},"page":"1343-1349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Underutilization of Staging Laparoscopy Prior to Neoadjuvant Systemic Therapy in Gastric Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Arsha","family":"Ostowari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bima J.","family":"Hasjim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaina","family":"Sedighim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Tajik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninh T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver S.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-8558","authenticated-orcid":false,"given":"Maheswari","family":"Senthil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"18547_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"18547_CR2","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results Program. 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html. Accessed 1 April 2025."},{"key":"18547_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138.","journal-title":"Int J Cancer"},{"key":"18547_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12957-017-1243-z","volume":"15","author":"B Hultman","year":"2017","unstructured":"Hultman B, Gunnarsson U, Nygren P, et al. Prognostic factors in patients with loco-regionally advanced gastric cancer. World J Surg Oncol. 2017;15:172.","journal-title":"World J Surg Oncol"},{"key":"18547_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jso.28095","volume":"132","author":"O Dobrzhanskyi","year":"2025","unstructured":"Dobrzhanskyi O, Gaskill CE, Kizub D, et al. Utilization of staging laparoscopy for patients with gastric cancer in Ukraine. J Surg Oncol. 2025;132:65\u20139.","journal-title":"J Surg Oncol"},{"key":"18547_CR6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/jso.25711","volume":"120","author":"K Rawicz-Pruszynski","year":"2019","unstructured":"Rawicz-Pruszynski K, Mielko J, Pudlo K, et al. Yield of staging laparoscopy in gastric cancer is influenced by Lauren histologic subtype. J Surg Oncol. 2019;120:1148\u201353.","journal-title":"J Surg Oncol"},{"key":"18547_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjsurg.2005.10.015","volume":"191","author":"AI Sarela","year":"2006","unstructured":"Sarela AI, Lefkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191:134\u20138.","journal-title":"Am J Surg"},{"key":"18547_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1245\/ASO.2005.03.065","volume":"12","author":"D Bentrem","year":"2005","unstructured":"Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12:347\u201353.","journal-title":"Ann Surg Oncol"},{"key":"18547_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ejso.2010.06.007","volume":"36","author":"M La Torre","year":"2010","unstructured":"La Torre M, Ferri M, Giovagnoli MR, et al. Peritoneal wash cytology in gastric carcinoma: Prognostic significance and therapeutic consequences. Eur J Surg Oncol. 2010;36:982\u20136.","journal-title":"Eur J Surg Oncol"},{"key":"18547_CR10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.21873\/anticanres.12892","volume":"38","author":"E Virgilio","year":"2018","unstructured":"Virgilio E, Giarnieri E, Giovaganoli MR, et al. Gastric cancer cells in peritoneal lavage fluid: a systematic review comparing cytological with molcular detection for diagnosis of peritoneal metastases and prediction of peritoneal recurrences. Anticancer Res. 2018;38:1255\u201362.","journal-title":"Anticancer Res"},{"issue":"2","key":"18547_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Cancer Netw"},{"key":"18547_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"18547_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"},{"key":"18547_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"18547_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"18547_CR16","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1245\/s10434-016-5409-7","volume":"23","author":"N Ikoma","year":"2016","unstructured":"Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23:4332\u20137.","journal-title":"Ann Surg Oncol"},{"key":"18547_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1245\/s10434-019-07624-0","volume":"27","author":"L Ji","year":"2020","unstructured":"Ji L, Selleck MJ, Morgan JW, et al. Gastric cancer peritoneal carcinomatosis risk score. Ann Surg Oncol. 2020;27:240\u20137.","journal-title":"Ann Surg Oncol"},{"key":"18547_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2025.43.4_suppl.327","volume":"43","author":"C Yan","year":"2025","unstructured":"Yan C, Yang Z, Shi Z, et al. Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized phase 3 DRAGON-01 Trial. J Clin Oncol. 2025;43:4.","journal-title":"J Clin Oncol"},{"key":"18547_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12885-023-10680-1","volume":"23","author":"M Senthil","year":"2023","unstructured":"Senthil M, Dayyani F. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial. BMC Cancer. 2023;23:209.","journal-title":"BMC Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18547-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18547-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18547-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:33:12Z","timestamp":1767573192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18547-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["18547"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18547-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}